TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative rate of Mucositis grade 2-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission for hyperbilirubinemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cognitive test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunogenicity of Flubio vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: observation of a disease or medical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD patient functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention rate (percent)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: compliance (percent)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of bladder volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Button clicks during a red cue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief pleasantness ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in total and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ASIA motor function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Half-Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieve Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COVID Disease Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of axis-1 disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Blood Loss Over Course of Stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in Preoperative and Lowest Postoperative Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Subscapularis repair integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Refractive Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Listening comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hip Abductor Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrhythmia Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Masseteric hypertrophy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at rest and movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate of acute cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of internet mindfulness meditation training sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Response (OR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IT-MAIS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Treatment Emergent Treatment-Related Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with injection site reaction(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with laboratory test findings of potential clinical importance
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with vital signs findings of potential clinical importance
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with ECG findings of potential clinical importance
Endpoint domain: Adverse events/effects
Primary endpoint: Development of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Sleep Quality score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Relapse rate 6 months after remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of mucin glycosylating enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive disease, complete or partial responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of vaginal delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Exhaled carbon monoxide and nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RVSP as surrogate of Pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative rate of open food challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all other toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged lymphopenia (lasting more than 12 weeks)
Endpoint domain: Adverse events/effects
Primary endpoint: mass balance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectivity of image-guided laser ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change on surface electromyography in gastrocnemius muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change on range of ankle motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peritoneal dialysis catheter survival (sustained function)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Positive Diagnosis of Pulmonary Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimum serum concentration (Cmin) of nitisinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biofunctional age (BFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in circulating BDNF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change From Baseline in Viral Quantitative e Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Laryngospasm Postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Early recurrence detection lead time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Body Mass Index (BMI) Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Measures of Academic Progress Reading Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mechanical Ventilation or Death
Endpoint domain: Mortality/survival
Primary endpoint: Sufficient neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stem anteversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined incidence of confirmed clinically relevant adverse events (CRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in LDL-C From Baseline to Day 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined prevalence of pre-diabetes and diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent changes in ultrasound-estimated bladder weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of ceftaroline fosamil
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery room resting pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral therapy (ART) medication adherence (suppression level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral therapy (ART) medication adherence (undetectable level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Symptoms Associated With ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inattentiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination inhibition antibody (HIA) titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with fever
Endpoint domain: Adverse events/effects
Primary endpoint: Percent reduction in the number of UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients able to return to sport activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in level of light chain neurofilaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in level of amyloid isoforms 40 and 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in level of daytime sleepiness - Epworth Sleepiness scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Engagement in outpatient HIV care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Level of Activity of Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Subjects With First Reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in mean morning PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Extent of pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of co-administration
Endpoint domain: Adverse events/effects
Primary endpoint: Cornea epithelial thickness distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum Trafermin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of contact lenses interactions with the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initiation of the comparison study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Steady State Plasma levels of Itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Successful Vaginal Birth
Endpoint domain: Mortality/survival
Primary endpoint: Successful LMA removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of subjects with viral load < 40 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-380 and D308
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-380 and D308
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride uptake into dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eligible Participants Enrolled Who Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Experiencing SAEs, Severe AEs (Grade 3), and/or IMEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Symptoms (Depression and Anxiety Scale - DASS 42 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Symptoms (Quality of Life Enjoyment and Satisfaction - Q-LES-Q)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Symptoms (Patient Health Questionnaire - PHQ 9 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child-Turcotte-Pugh (CTP) score >= 2 points from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of toxicities of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with a change in albumin + bilirubin (ALBI) level of >= 0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Symptom Scale (PANAS) rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of complete abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective exhaustion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Anatomical correction of the prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment, Retention, and Adherence Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety Reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Timed Functional Tests at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Functional testing at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Functional Testing at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of discount generic prescription programs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adenoma Miss Rate (AMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of Ranibizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Erythrocyte Fatty Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Total Subepithelial Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of complications during independent cases
Endpoint domain: Adverse events/effects
Primary endpoint: changes in gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Morning Peak Expiratory Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Freedom From Re-operation of the Index Meniscus Repair Site
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint of Asthma-related Events
Endpoint domain: Mortality/survival
Primary endpoint: Asthma Exacerbation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in vital signs and Body mass over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with a successful self-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Level of Ena-78
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Saturation recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hospitalizations for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Presence of Donor Lymphohematopoietic Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HRV frequency-domain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV time-domain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy of prophylaxis regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apoB-lipoprotein remnants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in faecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change From Baseline in Absolute OFF Time (Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological dimensions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes of oral microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of periodontal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-hydroxybutyrate AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: placebo-corrected mean maximal decrease in supine systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first blood stream infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to full recovery symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence Rate of Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of suspected glaucoma/glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Intestinal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of power development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-Peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total number of per-procedure Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fasting circulating LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant Pain Experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Remaining Off Inhaled Corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of positioning schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-peptide value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Psoriasis Area Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adequacy of low dose CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vaccine protective effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Quality of Life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Thyroid Eye Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference of metatarsal angles in degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of non-persistence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Myocardial Perfusion Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mid Perfusion Reserve Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anastomotic Leak Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Daily rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global and regional brain network alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects